3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Carcinoma, Non-Small-Cell Lung
132
Squamous Cell Carcinoma of Head and Neck
74
Lung Neoplasms
49
Head and Neck Neoplasms
44
Urinary Bladder Neoplasms
43
Parkinson Disease 4, Autosomal Dominant Lewy Body
33
Nasopharyngeal Carcinoma
32
Oropharyngeal Neoplasms
31
Biliary Tract Neoplasms
31
Uterine Cervical Neoplasms
29
Cholangiocarcinoma
28
Esophageal Squamous Cell Carcinoma
26
Carcinoma
24
Neoplasms
23
Ovarian Neoplasms
22
Neoplasm Metastasis
22
Small Cell Lung Carcinoma
21
Carcinoma, Squamous Cell
19
Stomach Neoplasms
18
Colorectal Neoplasms
18
Carcinoma, Transitional Cell
17
Pancreatic Neoplasms
16
Esophageal Neoplasms
16
Mesothelioma, Malignant
15
Gallbladder Neoplasms
15
Mouth Neoplasms
13
Laryngeal Neoplasms
13
Hypopharyngeal Neoplasms
12
Endometrial Neoplasms
11
Triple Negative Breast Neoplasms
10
Interventions
pembrolizumab
5
enfortumab vedotin
3
Gemcitabine
3
dodecyl maltoside
2
Sunitinib
2
Cisplatin
2
zidovudine 5'-monophosphate-mannose-albumin conjugate
1
tucatinib
1
testosterone 17 beta-cypionate
1
temsirolimus
1
relatlimab
1
palbociclib
1
niraparib
1
galactosamine-conjugated serum albumin-conjugated-(rhodamine X)20
1
cabozantinib
1
Valproic Acid
1
Urinary Diversion
1
Trastuzumab
1
Testosterone Propionate
1
Standard of Care
1
Sirolimus
1
Rivaroxaban
1
Ringer's acetate
1
Radiosurgery
1
Radiation Dose Hypofractionation
1
Psychiatric Nursing
1
Practice Guidelines as Topic
1
Physical Therapy Modalities
1
Nivolumab
1
Multiparametric Magnetic Resonance Imaging
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Urologic Neoplasms
×
Cisplatin
×
1 year
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled
NCT03288545
2026-03-24
EV-103
Astellas Pharma Inc
Phase 1/2
Terminated
348 enrolled
1 FDA